Abstract
Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Current Drug Targets
Title: A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Volume: 7 Issue: 9
Author(s): U. Taksh
Affiliation:
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Abstract: Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Export Options
About this article
Cite this article as:
Taksh U., A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia, Current Drug Targets 2006; 7 (9) . https://dx.doi.org/10.2174/138945006778226589
DOI https://dx.doi.org/10.2174/138945006778226589 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design DNA Minor Groove Binders: an Overview on Molecular Modeling and QSAR Approaches
Current Medicinal Chemistry Imaging of Pancreatic Beta-Cell Signal-Transduction
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Extraction, Characterization and In Vivo Neuromodulatory Activity of Phytosterols from Microalga Dunaliella Tertiolecta
Current Medicinal Chemistry Withdrawal Notice: Pharmacological analysis of Cannabis sativa L.: A potent herbal plant
Mini-Reviews in Medicinal Chemistry Methodological Aspects of Erythrocyte Aggregation
Recent Patents on Anti-Cancer Drug Discovery Role of Neuronal Guidance Cues in the Pathophysiology of Obesity: A Peripheral and Central Overview
Current Pharmaceutical Design Overcoming Cell Death and Tau Phosphorylation Mediated by PI3KInhibition: A Cell Assay to Measure Neuroprotection
CNS & Neurological Disorders - Drug Targets 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Neuronal Nicotinic Receptors and Neuroprotection: Newer Ligands May Help us Understand their Role in Neurodegeneration
Medicinal Chemistry Reviews - Online (Discontinued) Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Transcription, DNA Damage and Beyond: The Roles of Histone Ubiquitination and Deubiquitination
Current Protein & Peptide Science Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Paralog Specific Hsp90 Inhibitors – A Brief History and a Bright Future
Current Topics in Medicinal Chemistry Bioactive Compounds of <i>Polygonatum sibiricum</i> - Therapeutic Effect and Biological Activity
Endocrine, Metabolic & Immune Disorders - Drug Targets Psychological and Mental Health Issues During the SARS-CoV-2 Global Pandemic: A Critical Analysis
Coronaviruses Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets